BACKGROUND: Transforming growth factor-β1 (TGF-β1) has dual roles inhibiting and promoting carcinogenesis. Although many researchers have conducted association studies between TGFB1 C-509T polymorphism and the risk of developing gastric cancer, the results are not uniform. METHODS: We genotyped 1028 gastric cancer patients and 958 controls by the polymerase chain reaction-restriction fragment length polymorphism method. Immunohistochemistry was performed to assess the expression of TGF-β1 in the cancer and noncancerous tissues of 120 gastric cancer patients. mRNA expression was also measured in noncancerous gastric mucosa by qRT-PCR in the 282 subjects. RESULTS: The CT genotype in the TGFB1 C-509T polymorphism was associated with an increased risk of gastric cancer development (adjusted OR 1.35, 95 % CI 1.07-1.71, P = 0.013), especially for intestinal-type cancer (adjusted OR 1.43, 95 % CI 1.08-1.90, P = 0.014). More frequent TGF-β1 expression was found in the center of cancer tissue in the TGFB1-509T carrier group than in the others (90.5 % vs. 72.2 %, P = 0.010). T-carriers also presented higher expression level of gastric TGF-β1 mRNA than non T-carriers (median 1.29 vs. 0.80, P = 0.004) when they were infected by H. pylori. Cancer patients showed elevated gastric TGFB1gene expression compared to the control group (median 1.22 vs. 0.89, P = 0.009). CONCLUSIONS: The carcinogenic effect of TGF-β1 might be associated with increased gastric TGF-β1 expression in subjects with the T allele of TGFB1-509.
BACKGROUND: Transforming growth factor-β1 (TGF-β1) has dual roles inhibiting and promoting carcinogenesis. Although many researchers have conducted association studies between TGFB1C-509T polymorphism and the risk of developing gastric cancer, the results are not uniform. METHODS: We genotyped 1028 gastric cancerpatients and 958 controls by the polymerase chain reaction-restriction fragment length polymorphism method. Immunohistochemistry was performed to assess the expression of TGF-β1 in the cancer and noncancerous tissues of 120 gastric cancerpatients. mRNA expression was also measured in noncancerous gastric mucosa by qRT-PCR in the 282 subjects. RESULTS: The CT genotype in the TGFB1C-509T polymorphism was associated with an increased risk of gastric cancer development (adjusted OR 1.35, 95 % CI 1.07-1.71, P = 0.013), especially for intestinal-type cancer (adjusted OR 1.43, 95 % CI 1.08-1.90, P = 0.014). More frequent TGF-β1 expression was found in the center of cancer tissue in the TGFB1-509T carrier group than in the others (90.5 % vs. 72.2 %, P = 0.010). T-carriers also presented higher expression level of gastric TGF-β1 mRNA than non T-carriers (median 1.29 vs. 0.80, P = 0.004) when they were infected by H. pylori. Cancerpatients showed elevated gastric TGFB1gene expression compared to the control group (median 1.22 vs. 0.89, P = 0.009). CONCLUSIONS: The carcinogenic effect of TGF-β1 might be associated with increased gastric TGF-β1 expression in subjects with the T allele of TGFB1-509.
Authors: D J Grainger; K Heathcote; M Chiano; H Snieder; P R Kemp; J C Metcalfe; N D Carter; T D Spector Journal: Hum Mol Genet Date: 1999-01 Impact factor: 6.150
Authors: J T Comerci; C D Runowicz; K C Flanders; C De Victoria; A L Fields; A S Kadish; G L Goldberg Journal: Cancer Date: 1996-03-15 Impact factor: 6.860
Authors: Hye Seung Lee; Sung-Bum Cho; Hee Eun Lee; Min A Kim; Ji Hun Kim; Do Joong Park; Ju Han Kim; Han-Kwang Yang; Byung Lan Lee; Woo Ho Kim Journal: Clin Cancer Res Date: 2007-07-15 Impact factor: 12.531
Authors: Ignacio Juarez; Alberto Gutierrez; Christian Vaquero-Yuste; Elisa M Molanes-López; Adela López; Inmaculada Lasa; Remedios Gómez; José Manuel Martin-Villa Journal: J Cell Mol Med Date: 2020-12-04 Impact factor: 5.295